Literature DB >> 22414727

Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity.

Ramona Steri1, Janosch Achenbach, Dieter Steinhilber, Manfred Schubert-Zsilavecz, Ewgenij Proschak.   

Abstract

A self-organizing map (SOM) is a virtual screening method used for correlation of molecular structure and potential biological activity on a certain target and offers a way to represent multi-dimensional data of large databases in a two-dimensional space. Large databases, for example the DrugBank database, provide information about biological activity and chemical structure of small molecules and are widely used in drug development for identification of new lead structures. The farnesoid X receptor (FXR) is a ligand activated transcription factor involved in key regulation mechanisms within glucose and lipid homeostasis. Although FXR became an established target in drug development for diseases associated with lipid, glucose or hepatic disorders during the last decade, none of the developed compounds have reached later phases of clinical development so far. We used a SOM trained with known FXR ligands to screen the DrugBank database for potential ligands for FXR. In this article, we report the successful identification of six approved drugs out of the Drugbank as FXR modulators (ketoconazole, pentamidine, dobutamine, imatinib, papaverine and montelukast) by using a SOM for screening of the DrugBank database. We show FXR modulation by selected compounds in a full length FXR transactivation assay and modulation of a FXR target gene by imatinib.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22414727     DOI: 10.1016/j.bcp.2012.02.027

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

1.  Differential Therapeutic Effects of FXR Activation, sEH Inhibition, and Dual FXR/sEH Modulation in NASH in Diet-Induced Obese Mice.

Authors:  Moritz Helmstädter; Jurema Schmidt; Astrid Kaiser; Lilia Weizel; Ewgenij Proschak; Daniel Merk
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-29

2.  NSAIDs Ibuprofen, Indometacin, and Diclofenac do not interact with Farnesoid X Receptor.

Authors:  Jurema Schmidt; Franca-Maria Klingler; Ewgenji Proschak; Dieter Steinhilber; Manfred Schubert-Zsilavecz; Daniel Merk
Journal:  Sci Rep       Date:  2015-10-01       Impact factor: 4.379

3.  Chemically Advanced Template Search (CATS) for Scaffold-Hopping and Prospective Target Prediction for 'Orphan' Molecules.

Authors:  Michael Reutlinger; Christian P Koch; Daniel Reker; Nickolay Todoroff; Petra Schneider; Tiago Rodrigues; Gisbert Schneider
Journal:  Mol Inform       Date:  2013-02-07       Impact factor: 3.353

4.  In silico polypharmacology: retrospective recognition vs. rational design.

Authors:  Ewgenij Proschak
Journal:  J Cheminform       Date:  2014-03-11       Impact factor: 5.514

5.  Molecular tuning of farnesoid X receptor partial agonism.

Authors:  Daniel Merk; Sridhar Sreeramulu; Denis Kudlinzki; Krishna Saxena; Verena Linhard; Santosh L Gande; Fabian Hiller; Christina Lamers; Ewa Nilsson; Anna Aagaard; Lisa Wissler; Niek Dekker; Krister Bamberg; Manfred Schubert-Zsilavecz; Harald Schwalbe
Journal:  Nat Commun       Date:  2019-07-02       Impact factor: 14.919

6.  Quantitative proteomic study of the plasma reveals acute phase response and LXR/RXR and FXR/RXR activation in the chronic unpredictable mild stress mouse model of depression.

Authors:  Chuangchuang Yang; Chanjuan Zhou; Jie Li; Zhi Chen; Haiyang Shi; Wensong Yang; Yinhua Qin; Lin Lü; Libo Zhao; Liang Fang; Haiyang Wang; Zicheng Hu; Peng Xie
Journal:  Mol Med Rep       Date:  2017-10-20       Impact factor: 2.952

7.  Allosteric modulation of the farnesoid X receptor by a small molecule.

Authors:  Matthias Gabler; Jan Kramer; Jurema Schmidt; Julius Pollinger; Julia Weber; Astrid Kaiser; Frank Löhr; Ewgenij Proschak; Manfred Schubert-Zsilavecz; Daniel Merk
Journal:  Sci Rep       Date:  2018-05-01       Impact factor: 4.379

8.  Dual Farnesoid X Receptor/Soluble Epoxide Hydrolase Modulators Derived from Zafirlukast.

Authors:  Simone Schierle; Moritz Helmstädter; Jurema Schmidt; Markus Hartmann; Maximiliane Horz; Astrid Kaiser; Lilia Weizel; Pascal Heitel; Anna Proschak; Victor Hernandez-Olmos; Ewgenij Proschak; Daniel Merk
Journal:  ChemMedChem       Date:  2019-11-19       Impact factor: 3.466

Review 9.  Natural Products Targeting Liver X Receptors or Farnesoid X Receptor.

Authors:  Jianglian She; Tanwei Gu; Xiaoyan Pang; Yonghong Liu; Lan Tang; Xuefeng Zhou
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

10.  Development and in vitro Profiling of Dual FXR/LTA4H Modulators.

Authors:  Simone Schierle; Steffen Brunst; Moritz Helmstädter; Roland Ebert; Jan S Kramer; Dieter Steinhilber; Ewgenij Proschak; Daniel Merk
Journal:  ChemMedChem       Date:  2021-05-24       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.